LRI Investments LLC Takes $49,000 Position in Icon Plc $ICLR

LRI Investments LLC purchased a new stake in shares of Icon Plc (NASDAQ:ICLR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 334 shares of the medical research company’s stock, valued at approximately $49,000.

Several other institutional investors have also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its stake in Icon by 22.8% in the first quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company’s stock valued at $99,000 after purchasing an additional 110 shares during the last quarter. Wealthquest Corp purchased a new position in Icon in the first quarter valued at about $862,000. Transcend Capital Advisors LLC grew its stake in Icon by 7.6% in the first quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company’s stock valued at $205,000 after purchasing an additional 83 shares during the last quarter. Cloud Capital Management LLC purchased a new position in Icon in the first quarter valued at about $101,000. Finally, Whittier Trust Co. grew its stake in Icon by 9.2% in the first quarter. Whittier Trust Co. now owns 5,172 shares of the medical research company’s stock valued at $905,000 after purchasing an additional 436 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Price Performance

Shares of NASDAQ ICLR opened at $186.05 on Tuesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.29 and a current ratio of 1.29. The company has a market cap of $15.03 billion, a PE ratio of 19.14, a P/E/G ratio of 2.72 and a beta of 1.23. The business has a 50-day simple moving average of $174.99 and a two-hundred day simple moving average of $156.75. Icon Plc has a fifty-two week low of $125.10 and a fifty-two week high of $301.45.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The firm had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the previous year, the company posted $3.75 earnings per share. The company’s revenue was down 4.8% compared to the same quarter last year. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, equities analysts expect that Icon Plc will post 13.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ICLR has been the topic of several analyst reports. Rothschild & Co Redburn upgraded Icon from a “neutral” rating to a “buy” rating and lifted their target price for the company from $184.00 to $236.00 in a research note on Wednesday, September 3rd. Evercore ISI lifted their target price on Icon from $170.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Rothschild Redb upgraded Icon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Icon in a report on Wednesday, October 8th. Finally, Citigroup reissued a “neutral” rating and issued a $200.00 price target (down previously from $225.00) on shares of Icon in a report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $210.64.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.